How does CMRT work?
CMRT focuses on the premise that most harmful pharmacological or
toxic encounters in the body will also form a parallel immune system
challenge. The immune system recognizes the presence of a foreign
substance, identifies its nature and then mounts a defensive action
against it. Part of that defensive action is the production of specific
antibodies which contribute to neutralizing the targeted foreign
substance, destroying or altering its structure and binding the
substance preparatory to its removal from the encounter site and
elimination from the system.
Even after the offending foreign substance can no longer be detected
in body fluids and tissues, the specific antibodies against it remain
present in the plasma/serum of the blood for a period of months
to years. Additional quantities of the specific antibody can be
quickly produced in the future if needed due to certain memory lymphatic
cells which have a long-term, enduring record of the antibody which
counters the foreign substance. These memory cells will facilitate
a quick response with replenishment of antibodies in the blood as
Sadly, the immune system is not especially effective in protecting
the patient when it comes to the foreign substances such as those
associated with restorative and reconstruction biomaterials. However,
the requisite antibody response still takes place and the antibodies
remain for extended periods of time. Detecting those antibodies
at or above a relevant clinical threshold level is a useful indicator
that the patient has experienced an adverse encounter with the offending
substance and has developed a systemic sensitivity to it.
CMRT looks for the presence of antibodies in patient serum at or
above a relevant threshold which have been formed against the chemical
groups and families of compounds that can be released from restorative
and reconstruction biomaterials. The contributing source which
initiated the creation of the antibodies is somewhat immaterial.
Whether the offending substance first came from prior placement
of the substance as part of a medical or dental procedure, or whether
it came from food, water or environmental contact sources, once
the body becomes sensitized it will react with the substance from
any future source.
Thus, if the patient has become sensitized to the offending substance
from any source whatsoever, the dentist or physician will want to
avoid placing new biomaterials which can exacerbate that existing
sensitivity. CMRT identifies the reactive chemical group or family,
and then correlates that finding with our database of biomaterials
by trade-name. At the same time, it also indicates all products
in the database by trade-name which have not shown any contraindicating
components. The healthcare professional can easily check available
biomaterials and identify those to avoid for the patient.